Novel immunotherapies in multiple myeloma - chances and challenges

被引：24

作者：

Rasche, Leo ^{[1
,2
]}

Wasch, Ralph ^{[3
]}

Munder, Markus ^{[4
,5
]}

Goldschmidt, Hartmut ^{[6
,7
]}

Raab, Marc S. ^{[6
,8
]}

机构：

[1] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[2] Univ Hosp Wurzburg, Mildred Scheel Early Career Ctr, Wurzburg, Germany

[3] Univ Freiburg, Fac Med, Univ Med Ctr, Dept Internal Med 1, Freiburg, Germany

[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[5] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Res Ctr Immunotherapy, Mainz, Germany

[6] Univ Hosp Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[7] Natl Ctr Tumor Dis NCT, Heidelberg, Germany

[8] German Canc Res Ctr, CCU Mol Hematol Oncol, Heidelberg, Germany

来源：

HAEMATOLOGICA | 2021年 / 106卷 / 10期

关键词：

T-CELL THERAPY; CAR-T; EXPRESSION; CD38;

D O I：

10.3324/haematol.2020.266858

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In this review article, we summarize the latest data on antibody-drug conjugates, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells in the treatment of multiple myeloma. We discuss the pivotal questions to be addressed as these new immunotherapies become standard agents in the management of multiple myeloma. We also focus on the selection of patients for these therapies and speculate as to how best to individualize treatment approaches. We see these novel immunotherapies as representing a paradigm shift. However, despite the promising preliminary data, many open issues remain to be evaluated in future trials.

引用

页码：2555 / 2565

页数：11

共 50 条

[1] Novel Immunotherapies for Multiple Myeloma
Mattia D’Agostino
Mario Boccadoro
Eric L. Smith
Current Hematologic Malignancy Reports, 2017, 12 : 344 - 357
[2] Novel immunotherapies in multiple myeloma
Ken Ohmine
Ryosuke Uchibori
International Journal of Hematology, 2022, 115 : 799 - 810
[3] Novel immunotherapies in multiple myeloma
Ohmine, Ken
Uchibori, Ryosuke
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (06) : 799 - 810
[4] Novel Immunotherapies for Multiple Myeloma
D'Agostino, Mattia
Boccadoro, Mario
Smith, Eric L.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (04) : 344 - 357
[5] Development of Novel Immunotherapies for Multiple Myeloma
Al-Hujaily, Ensaf M.
Oldham, Robyn A. A.
Hari, Parameswaran
Medin, Jeffrey A.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2016, 17 (09)
[6] A new era of novel immunotherapies for multiple myeloma
Kazandjian, Dickran
Landgren, Ola
LANCET, 2021, 398 (10301): : 642 - 643
[7] Multiple Myeloma Immunotherapies
Podar, Klaus
CURRENT CANCER DRUG TARGETS, 2017, 17 (09) : 768 - 768
[8] Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions
Zhi-Ling Yan
Yue-Wen Wang
Ying-Jun Chang
Oncology and Therapy, 2022, 10 : 85 - 103
[9] Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions
Yan, Zhi-Ling
Wang, Yue-Wen
Chang, Ying-Jun
ONCOLOGY AND THERAPY, 2022, 10 (01) : 85 - 103
[10] NK Cell States in Multiple Myeloma: Pathways to Novel Immunotherapies
Uerga, Jacopo Umberto
Szegezdi, Eva
Broin, Pilib O.
O'Dwyer, Michael
Dalaigh, Micheal O.
Hu, Wanshan
BLOOD, 2024, 144 : 6857 - 6858

← 1 2 3 4 5 →